ĐÁNH GIÁ HOẠT TÍNH IN SILICO CỦA MỘT SỐ CÁC HỢP CHẤT XANTHONE TỪ SINH VẬT BIỂN NHƯ CÁC CHẤT ỨC CHẾ PI3Kγ BẰNG PHƯƠNG PHÁP GẮN KẾT PHÂN TỬ
Thông tin bài báo
Ngày nhận bài: 05/02/24                Ngày hoàn thiện: 29/02/24                Ngày đăng: 29/02/24Tóm tắt
Từ khóa
Toàn văn:
PDFTài liệu tham khảo
[1] J. Zugazagoitia, C. Guedes, S. Ponce, I. Ferrer, S. Molina-Pinelo, and L. Paz-Ares, “Current challenges in cancer treatment,” Clinical therapeutics, vol. 38, no.7, pp. 1551-1566, 2016.
[2] T. A. Baudino, “Targeted cancer therapy: the next generation of cancer treatment,” Current drug discovery technologies, vol. 1, no. 1, pp. 3-20, 2015.
[3] S. H. Hassanpour and M. Dehghani, “Review of cancer from perspective of molecular,” Journal of cancer research and practice, vol. 4, no. 4, pp. 127-129, 2017.
[4] N. E. Lopez, C. Prendergast, and A. M. Lowy, “Borderline resectable pancreatic cancer: definitions and management,” World journal of gastroenterology: WJG, vol. 20, no. 31, 2014, Art. no. 10740.
[5] J. M. Shafritz, International encyclopedia of public policy and administration. Routledge, New York 2019.
[6] J. Downward, “Targeting RAS signalling pathways in cancer therapy,” Nature reviews cancer, vol. 3, no. 1, pp. 11-22, 2003.
[7] K. E. O’Reilly, F. Rojo, Q. B. She, D. Solit, G. B. Mills, D. Smith, and N. Rosen, “mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt,” Cancer research, vol. 66, no. 3, pp. 1500-1508, 2006.
[8] P. Liu, H. Cheng, T. M. Roberts, and J. J. Zhao, “Targeting the phosphoinositide 3-kinase pathway in cancer,” Nature reviews Drug discovery, vol. 8, no. 8, pp. 627-644, 2009.
[9] J. A. Brazzatti, M. Klingler-Hoffmann, S. Haylock-Jacobs, Y. Harata-Lee, M. Niu, M. D. Higgins, and S. R. McColl, “Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis,” Oncogene, vol. 31, no. 18, pp. 2350-2361, 2012.
[10] P. Liu, H. Cheng, T. M. Roberts, and J. J. Zhao, “Targeting the phosphoinositide 3-kinase pathway in cancer,” Nature reviews Drug discovery, vol. 8, no. 8, pp. 627-644, 2009.
[11] X. Qiu, Y. Tian, Z. Liang, Y. Sun, Z. Li, and J. Bian, “Recent discovery of phosphoinositide 3-kinase γ inhibitors for the treatment of immune diseases and cancers,” Future medicinal chemistry, vol. 11, no. 16, pp. 2151-2169, 2019.
[12] D. Y. Gu, M. M. Zhang, J. Li, Y. B. Zhou, and R. Sheng, “Development of PI3Kγ selective inhibitors: the strategies and application,” Acta Pharmacologica Sinica, vol. 45, pp. 1-10, 2023.
[13] J. X. Soares, D. R. Loureiro, A. L. Dias, S. Reis, M. M. Pinto, and C. M. Afonso, “Bioactive marine xanthones: A review,” Marine Drugs, vol. 20, no. 1, p. 58, 2022.
[14] D. R. Loureiro, J. X. Soares, J. C. Costa, Á. F. Magalhães, C. M. Azevedo, M. M. Pinto, and C. M. Afonso, “Structures, activities and drug-likeness of anti-infective xanthone derivatives isolated from the marine environment: a review,” Molecules, vol. 24, no. 2, p. 243, 2019.
[15] A. C. Veríssimo, D. C. Pinto, and A. M. Silva, “Marine-derived xanthone from 2010 to 2021: Isolation, bioactivities and total synthesis,” Marine Drugs, vol. 20, no. 6, p. 347, 2022.
[16] Y. Na, “Recent cancer drug development with xanthone structures,” Journal of Pharmacy and Pharmacology, vol. 61, no. 6, pp. 707-712, 2009.
[17] S. T. Grabacki, Y. V. Pathak, and N. H. Joshi, (Eds.), Marine-Based Bioactive Compounds: Applications in Nutraceuticals. CRC Press, 2022.
[18] Y. S. Kurniawan, K. T. A. Priyangga, P. H. D. Jumina, E. N. Sholikhah, A. K. Zulkarnain, H. A. Fatimi, and J. Julianus, “An update on the anticancer activity of xanthone derivatives: A review,” Pharmaceuticals, vol. 14, no.11, p. 1144, 2021
[19] T. A. Halgren, “MMFF VI. MMFF94s option for energy minimization studies,” Journal of computational chemistry, vol. 20, no. 7, pp. 720-729, 1999.
[20] P. T. Le, H. Cheng, S. Ninkovic, M. Plewe, X. Huang, H. Wang, and E. Zhang, “Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR,” Bioorganic & medicinal chemistry letters, vol. 22, no. 15, pp. 5098-5103, 2012.
[21] J. Eberhardt, D. Santos-Martins, A. F. Tillack, and S. Forli, “AutoDock Vina 1.2. 0: New docking methods, expanded force field, and python bindings,” Journal of chemical information and modeling, vol. 61, no. 8, pp.3891-3898, 2021.
[22] T. H. Tran, T. T. Phan, T. T. Vi, X. H. Nguyen, V. H. Nguyen, N. H. Nguyen, T. H. D. Nguyen, H. T. Nguyen, H. T. Nguyen, V. C. Tran, T. T. H. Nguyen, and D. G. Le, “Chemical composition and antimicrobial activity of essential oil obtained from the rhizomes of Kaempferia champasakensis: in vitro and molecular docking studies,” Journal of Essential Oil Bearing Plants, vol. 26, no. 4, pp. 958-969, 2023.
[23] T. T. L. Vu, V. H. Hoang, X. H. Nguyen, H. L. Cao, T. H. M. Pham, and T. L. Do, “Natural Phosphodiesterase-4 Inhibitorswith Potential Anti-InflammatoryActivities from Millettia dielsiana,” Molecules, vol. 28, no. 21, p. 7253, 2023.
[24] T. T. L. Vu, V. H. Dao, M. Q. Bui, T. H. M. Pham, and T .L. Do, “Hepatoprotective Effect of Millettia dielsiana: In Vitro and In Silico Study,” Molecules, vol. 27, no. 24, p. 8978, 2022.
[25] G. M. Morris and M. Lim-Wilby, “Molecular docking,” Molecular modeling of proteins, Springer, 2008, pp. 365-382.
[26] S. Agarwal and R. J. J. C. Mehrotra, “An overview of molecular docking,” JSM chem., vol. 4, no. 2 pp. 1024-1028, 2016.
[27] R. Arora and L. Tchertanov, The HIV-1 integrase: modeling and beyond, INTECH, 2012.
[28] A. K. Bronowska, “Thermodynamics of ligand-protein interactions: implications for molecular design,” in Thermodynamics-Interaction Studies-Solids, Liquids and Gases. IntechOpen, 2011.
[29] M. Q. Lu, J. Y. Ruan, H. M. Li, D. S. Yang, Y. X. Liu, M. M. Hao, and T. Wang, “Xanthones from Gentianella acuta (Michx.) Hulten Ameliorate Colorectal Carcinoma via the PI3K/Akt/mTOR Signaling Pathway,” International Journal of Molecular Sciences, vol. 24, no. 3, p. 2279, 2023.
DOI: https://doi.org/10.34238/tnu-jst.9680
Các bài báo tham chiếu
- Hiện tại không có bài báo tham chiếu